7 140 anti-citrullinated protein/peptide antibody (ACPA) level.
141
Disease activity was assessed by calculating DAS28-CRP for each patient at each 142 visit. The DAS28-CRP was calculated, and patients were categorized into the following four 143 groups: remission, low (LDA), moderate (MDA), or high (HDA) disease activity according 144 to the recommended formula 145 (https://www.das-score.nl/das28/en/difference-between-the-das-and-das28/how-to-measure-t 146 he-das28/how-to-calculate-the-das28/alternative-validated-formulae.html). Because 147 DAS28-CRP values are reportedly lower than those obtained in the original DAS28
148 assessment using erythrocyte sedimentation rate, a threshold of 4.1 (instead of the original 149 5.1) was used as the cut-off for HDA; 2.7 (instead of 3.2) as the cut-off for low disease LDA;
150 and 2.3 (instead of 2.6) as the cut-off for remission [21] . The therapeutic response to ABA at 151 24 weeks was evaluated using the European League Against Arthritis (EULAR) response 152 criteria 153 (https://www.das-score.nl/das28/en/difference-between-the-das-and-das28/importance-of-das 154 28-and-tight-control/eular-response-criteria.html), with 4.1 and 2.7 used as the thresholds for 155 HDA and LDA, respectively. Briefly, patients were classified into three groups based on their 156 6-month DAS28-CRP and their absolute change from baseline according to the EULAR 
247
We analyzed the subtype of peripheral blood T cells before and four weeks after ABA 248 treatment (Fig 1a) ; furthermore, in each cell group, Ki67 expression was determined by flow 249 cytometry as a cell proliferation marker. 252 was confirmed using Rh-123 (Fig 1b) . The results showed that MDR-1 was highly expressed 253 only in Th17.1 cells and not in the Th1 and Th17 cells, as reported so far. The expression rate 254 of CD28, an inhibitory target in ABA treatment, in the Th17.1 cells was as high as that in the 255 others (>99%) (Fig 1c) . 275 Th subset. However, noticeable changes were not observed (Fig 2a) . Therefore, we next 276 analyzed the expression of Ki67 in the cells to confirm the early effects of ABA on each Th 277 cell subset (Fig 2b) . Before ABA treatment, the proportion of Ki67 positive cells among each 278 Th subset was different; particularly, the expression rate in Th17.1 cells was remarkably 279 lower than that in the other subsets (S2 Fig, Figs 2b and 2c) . In contrast, the expression rate 280 of Ki67 in Treg cells was relatively higher, which suggests that Treg is active during cell 281 proliferation in patients with RA. Next, the Ki67 positivity rate for each Th subset was 282 determined after ABA treatment for 4 four weeks and compared with the baseline. In only 4 14 283 weeks, the proportion of Ki67 positive cells was significantly reduced in all subsets other 284 than the Th17.1 cells (Fig 2c) . The change in Ki67 expression in Th17.1 cells was not 285 statistically significant (p = 0.39). 297 Data were analyzed using Wilcoxon signed rank test.
298
299 Therapeutic response to ABA and baseline Th17.1 300 ABA treatment was continued for 24 weeks, and the progress of disease activity in 301 each patient and the responsiveness to ABA treatment were evaluated. Subsequently, we 302 analyzed the correlation between ABA response and the Th subset at baseline. A remarkable 303 finding was that the proportion of baseline Th17.1 cells among CD4+ T cells in good 304 responders was significantly lower than that in poor responders (p = 0.0064) (Fig 3a) . In 305 contrast, no significant difference was observed with respect to the other Th subsets.
306
The attenuation of disease activity (DAS28-CRP) after 24 weeks of ABA treatment 307 also showed a significant negative correlation with Th17.1 (both percentage and absolute 15 308 number) (Fig 3b) . 
330
To assess the clinical relevance of the correlation between Th17.1 cells and ABA 331 response, we divided the patients into two groups (lower and higher) using the median Th 332 17.1 proportion (/CD4+) as cut-off (Table 2) , and into three groups (lowest, intermediate, and
16
333 highest) based on tertiles. ABA treatment response in each group was analyzed. Treatment 334 response was significantly different in the three groups (p = 0.019) (Fig 3c) . The treatment 335 response in the Th17.1-lower (lowest) group was significantly better than that in the higher 336 (highest) group (S3a-S3b Figs). On analysis of the trend of disease activity at 24 weeks, a 337 lower proportion of Th17.1 cells at baseline was associated with a higher percentage of 338 remission (Fig 3d) . Remission rates in the Th17.1-lower and lowest groups were 55% and 339 57.1%, respectively, and no remission was observed in the higher and highest groups. 343 Enrolled patients (n = 40) were stratified into two groups based on the median proportion of
